A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study)
Latest Information Update: 08 May 2024
At a glance
- Drugs Varenicline (Primary)
- Indications Neurotrophic keratopathy
- Focus Therapeutic Use
- Acronyms OLYMPIA
- Sponsors Oyster Point Pharmaceuticals
- 02 Jun 2023 Status changed from active, no longer recruiting to completed.
- 15 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2022 According to an Oyster Point Pharma media release, enrollment completed in this trial with data readout expected in Q1 23.